in the race to find a treatment for the virus that’s now sickened over 88,000 and killed over 3,000.
BrightGene also has not been licensed by the patent owner — Gilead — to make the drug, nor has it obtained “the relevant qualifications” for mass production of the therapy, said the stock exchange. Shares fell by the daily limit of 20% intraday on Monday. Gilead’s experimental drug, which has not been licensed or approved for use anywhere in the world, is being tested in clinical trials at hospitals in the central Chinese city of Wuhan, the epicenter of the coronavirus outbreak, as well as in other Asian nations.on Feb. 12 that it had managed to manufacture remdesivir in mass quantities garnered global headlines and sent its stock up nearly 60% last month to touch a record high.
BrightGene, for example, had only been able to make remdesivir in a small quantity for clinical research and not commercial production and its elision of this difference led to the spread of “unclear, inaccurate information,”BrightGene’s board secretary Wang Zhengye, who gave interviews to local media outlets saying the company’s drug is not for just for laboratory use but for mass production, was alsoWith the virus now being reported in over 65 countries, exuberance among investors and medical...
The design and execution of some of these trials have raised concerns among scientists, according to an
Leave decency to the CHINESE.